Kentucky is currently home to 1035 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
NCT02075775
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: Orthopaedic Institute of Western Kentucky, Paducah, Kentucky
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
CERENOVUS Neurothrombectomy Devices Registry
NCT05591183
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: Norton Neurology Institute, Elizabethtown, Kentucky
Conditions: Cerebral Stroke
Register for Updates
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
NCT04669548
Recruiting
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2022
Locations: Jewish Hospital / University of Louisville, Louisville, Kentucky
Conditions: Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
Register for Updates
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
NCT04845217
Recruiting
The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
08/19/2022
Locations: Springs Medical Center, Louisville, Kentucky
Conditions: Interstitial Cystitis
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Breast Cancer
Register for Updates
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591
Recruiting
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2022
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: C-Met Exon 14 Mutation
Register for Updates
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825
Recruiting
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Baptist Health Clinical Research, Elizabethtown, Kentucky
Conditions: Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Register for Updates
NSAIDS vs Opioids in Tibial Fractures
NCT05332314
Recruiting
This study will attempt to determine if there is a statistic difference between the time to union, non-union rate and post-operative pain of patients who receive opioids for pain control vs. patients who receive NSAIDs and a reduced dosage of opioids for pain management
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
04/15/2022
Locations: University of Louisville Hospital, Louisville, Kentucky
Conditions: Trauma
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Louisville, Kentucky
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT01638676
Recruiting
The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical activity of the combined regiment. Based on pre-clinical studies and a phase I trial, the investigators hypothesize that the combination of an FDA-approved non-toxic dose of oral Metformin with Vemurafenib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2021
Locations: James Graham Brown Cancer Center-University of Louisville, Louisville, Kentucky
Conditions: Melanoma
Register for Updates
Evaluation of SUMMIT BRUSH in Treatment of Blepharitis
NCT04603222
Recruiting
Dry Eye Disease (DED) is a multifactorial disease that affects \~15-30 million people in the USA alone. It creates an enormous societal and economic burden, decreases productivity in the workplace, and affects the quality of lives of the people affected by this disease. DED is primarily caused by blepharitis, a chronic inflammation of the eyelid margins. If left untreated, blepharitis results in the obstruction and loss of the glands responsible for tear film production. The standard of care is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2020
Locations: Kentucky Eye Institute, Lexington, Kentucky
Conditions: Blepharitis
Register for Updates